Vincerx Pharma (VINC)
(Delayed Data from NSDQ)
$0.75 USD
0.00 (-0.03%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $0.75 0.00 (0.03%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum C VGM
Income Statements
Fiscal Year end for Vincerx Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 43 | 74 | 63 | 11 | 0 |
Income After Depreciation & Amortization | -43 | -74 | -63 | -11 | 0 |
Non-Operating Income | 2 | 8 | 23 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -40 | -65 | -39 | -11 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -40 | -65 | -39 | -11 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -40 | -65 | -39 | -11 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -42 | -73 | -62 | -11 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -43 | -74 | -63 | -11 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 21.30 | 21.03 | 17.18 | 5.25 | NA |
Diluted EPS Before Non-Recurring Items | -1.89 | -3.11 | -3.65 | -2.04 | NA |
Diluted Net EPS (GAAP) | -1.89 | -3.11 | -2.29 | -2.04 | NA |
Fiscal Year end for Vincerx Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 7.48 | 5.53 | 10.32 | 11.66 | 15.10 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.48 | -5.53 | -10.32 | -11.66 | -15.10 |
Non-Operating Income | -4.95 | 0.58 | 0.60 | 0.51 | 0.76 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -12.43 | -4.95 | -9.72 | -11.15 | -14.34 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -12.43 | -4.95 | -9.72 | -11.15 | -14.34 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -12.43 | -4.95 | -9.72 | -11.15 | -14.34 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 21.40 | 21.37 | 21.35 | 21.27 | 21.19 |
Diluted EPS Before Non-Recurring Items | -0.34 | -0.23 | -0.46 | -0.52 | -0.68 |
Diluted Net EPS (GAAP) | -0.58 | -0.23 | -0.46 | -0.52 | -0.68 |